268: Biogen's sticky situation, Wegovy's risks, & biotech insider trading
The Readout Loud
00:00
Biogen's Boardroom Scandal
Damien Ross: Biogen's second quarter earnings call was interesting. He says the company faced a boardroom scandal involving its new CEO, Chris V. Bocker. This came after years of what people perceived as dysfunction at the highest levels of biogen, he says. Ross: It seemed like it was clearly a topic that he didn't want to talk about on the call.
Transcript
Play full episode
